drugset
drugset / Trial / NCT01718652

A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers

NCT01718652 ↗

Phase 1 Completed 18 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how a single dose of cyclosporin affects the pharmacokinetics (ie, how the body affects the drug) of multiple doses of canagliflozin (JNJ-28431754). The safety and tolerability of canagliflozin will also be assessed in healthy volunteers.

Timeline

Start
2011-02
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral
Subject Cyclosporine Peptide 400 mg Oral

Indications

No indication recorded.